Objective. To evaluate the efficacy and safety of the telmisartan plus amlodipine (T/A) single-pill combination (SPC) in Asian\npatients with hypertension whose blood pressure (BP) was not adequately controlled on either monotherapy or on low-dose\ncombination therapy. Patients and Methods. Data are presented from five Boehringer Ingelheim-sponsored phase 3, double-blind,\n8-week, studies: two studies in nonresponders to amlodipine (data pooled for amlodipine), two studies on nonresponders to\ntelmisartan (pooled data), and one on nonresponders to low-dose T/A SPC. Results. After 8 weeks� treatment, mean reductions\nfrom the reference baseline in diastolic BP (DBP; primary endpoint), systolic BP (SBP), and SBP, DBP goal, and response rates\nwere higher with the T/A SPC than respective monotherapies. The T80/A5 SPC resulted in greater reductions in DBP and SBP,\nand higher DBP goal and response rate than the low-dose T40/A5 SPC. Peripheral edema incidence was low (amlodipine 0.5%,\ntelmisartan 0.0%, and T/A SPC 0.7%). Discussion and Conclusion. In Asian patients whose BP is not adequately controlled with\ntelmisartan or amlodipine monotherapy, T/A SPC treatment results in greater BP reduction, and higher DBP and SBP goal and\nresponse rates. The safety and tolerability of the T/A SPC are comparable to those of the respective monotherapies and consistent\nwith those reported in previous studies.
Loading....